# FDA recall D-0958-2017

> **AstraZeneca Pharmaceuticals, LP** · Class I · drug recall initiated 2017-05-25.

## Product

BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE  19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.

## Reason for recall

Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.

## Distribution

Nationwide in the USA and Puerto Rico to physician offices.

## Key facts

- **Recall number:** D-0958-2017
- **Recalling firm:** AstraZeneca Pharmaceuticals, LP
- **Classification:** Class I
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2017-05-25
- **Report date:** 2017-07-19
- **Termination date:** 2018-04-24

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Newark, DE, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0958-2017

## Citation

> AI Analytics. FDA recall D-0958-2017. Retrieved 2026-06-26 from https://api.ai-analytics.org/recall/D-0958-2017. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*